Common use of LILLY's Option to Manufacture Clause in Contracts

LILLY's Option to Manufacture. Notwithstanding the foregoing, after Product Launch, LILLY shall have the option to manufacture up to [ * ] of the requirement of stable Ribozyme bulk drug required for the sale of the Ribozyme Product. In consideration of this option, and in the event LILLY manufactures the Ribozyme Product provided herein, LILLY shall increase the Royalty due RPI under Section 6.5.1 by up to [ * ], provided such manufacture by LILLY is not due to a failure by RPI to provide the required quantity of the bulk drug. Failure by RPI shall mean failure to provide required bulk drug in the required quantities to LILLY as described [ * ] Confidential treatment requested in the R&D Plan. The increase in the Royalty due RPI shall be determined using the following formula: [ * ]

LILLY's Option to Manufacture. Notwithstanding the foregoing, after Product Launch, LILLY shall have the option to manufacture up to [ * ] of the requirement [*] Confidential treatment requested 22 of stable Ribozyme bulk drug required for the sale of the Ribozyme Product. In consideration of this option, and in the event LILLY manufactures the Ribozyme Product provided herein, LILLY shall increase the Royalty due RPI under Section 6.5.1 by up to [ * ], provided such manufacture by LILLY is not due to a failure by RPI to provide the required quantity of the bulk drug. Failure by RPI shall mean failure to provide required bulk drug in the required quantities to LILLY as described [ * ] Confidential treatment requested in the R&D Plan. The increase in the Royalty due RPI shall be determined using the following formula: [ * ]

LILLY's Option to Manufacture. Notwithstanding the foregoing, after Product Launch, LILLY shall have the option to manufacture up to [ * [*] of the requirement of stable Ribozyme bulk drug required for the sale of the Ribozyme Product. In consideration of this option, and in the event LILLY manufactures the Ribozyme Product provided herein, LILLY shall increase the Royalty due RPI under Section 6.5.1 by up to [ * [*], provided such manufacture by LILLY is not due to a failure by RPI to provide the required quantity of the bulk drug. Failure by RPI shall mean failure to provide required bulk drug in the required quantities to LILLY as described [ * ] Confidential treatment requested in the R&D Plan. The increase in the Royalty due RPI shall be determined using the following formula: [ * ][*] [*] Confidential treatment requested